Introduction
Systemic lupus erythematosus (SLE) is a prototypic autoimmune disease that can affect multiple organs. Production of autoreactive Abs triggers formation of immune complexes (IC), which are widely deposited and lead to organ dysfunction. Renal involvement in SLE is known as lupus nephritis (LN). LN affects 40%-60% of adult SLE patients (1) and is characterized by Ab and complement deposition in the kidneys (2, 3) . IC deposition initiates recruitment and activation of neutrophils and monocytes that produce inflammatory mediators to amplify injury, often resulting in irreversible loss of renal function, i.e., endstage fibrosis (4) (5) (6) .
Evidence has accumulated supporting a role of the cell-surface metalloprotease A disintegrin and metalloprotease 17 (ADAM17), a principal sheddase for release of a variety of membrane-anchored substrates, including TNF-α and EGFR ligands (7, 8) in SLE. Peripheral blood mononuclear cells (PBMCs) of SLE patients show increased Adam17 expression (9) . Soluble shedding substrates of ADAM17 have been found in the plasma and urine of lupus mice and SLE patients, and some of these soluble factors are elevated prior to flare (10) (11) (12) . Among these, 2 major ADAM17 substrates, TNF-α and heparin-binding EGF (HB-EGF) (7, 8) , have been separately implicated as important mediators of kidney damage in lupus (13, 14) .
Although blocking ADAM17 could simultaneously shut down multiple pathogenic pathways and has been proposed for treating chronic kidney diseases not related to LN (15) (16) (17) , there are substantial concerns about therapeutically targeting ADAM17, mainly because ADAM17 has an essential role in protecting the skin and intestinal barrier through activating the EGFR pathway (18, 19) . Indeed, mice lacking Adam17 die at birth due to defects in EGFR signaling, and individuals with ADAM17 mutation or those treated with EGFR inhibitors display skin and intestinal inflammation (20) (21) (22) .
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Inactivation of iRhom2 in Fcgr2b
-/-mice (Fcgr2b
Rhbdf2
-/-mice) prevented disease-related mortality, severe proteinuria, and elevated blood urea nitrogen (BUN) in Fcgr2b -/-mice at 7 to 9 months of age ( Figure 1 , A-C).
Histological analysis of Fcgr2b -/-kidneys revealed glomerular and tubulo-interstitial injury characteristic of LN, including glomerular hypercellularity and crescents as well as interstitial inflammation and fibrosis. These were markedly attenuated in the absence of iRhom2 ( Figure 1D ). Transmission electron microscopy demonstrated loss of glomerular filtration barrier integrity with damaged podocyte foot processes, fenestra, and glomerular basement membranes in Fcgr2b -/-kidneys, whereas Fcgr2b
-/-mice were protected from these defects ( Figure 2A ). Inactivation of iRhom2 also prevented downregulation of podocin, an indicator of podocyte damage and loss ( Figure 2B ), and upregulation of kidney injury molecule-1 (KIM-1)/T cell Ig and mucin domain-1 (TIM-1), a marker for glomerular and tubular injury, in Fcgr2b -/-kidneys ( Figure 2C ). Interestingly, absence of iRhom2 did not alter serum levels of anti-dsDNA Abs ( Figure 2D ).
In the kidneys of Fcgr2b -/-mice, the extent of IC deposition (staining for mouse IgG) and complement C3 was not altered by absence of iRhom2 ( Figure 3A) . However, flow cytometry revealed a marked increase in CD45 + leukocytes in Fcgr2b -/-kidneys, including macrophages, neutrophils, monocytes, and CD4 + T cells, as compared with WT (Fcgr2b
-/-kidneys. Notably, inflammatory cell infiltration was significantly decreased eral EGFR ligands, including HB-EGF and amphiregulin, but not TGF-α, which is crucial for skin and intestinal barrier protection (25) . These unique properties of iRhom2 raised the intriguing possibility that targeting iRhom2 would provide an advantage over targeting ADAM17 and allow simultaneous inactivation of multiple pathways, including TNF-α and EGFR signaling in the effector cells involved in LN. However, the translational relevance of this attractive concept has never been tested directly in vivo.
The inhibitory Fc γ receptor IIB (Fcgr2b) is essential for maintaining tolerance, and its polymorphism is associated with lupus (29) . Fcgr2b-deficient mice spontaneously develop lupuslike syndromes, including production of anti-double-stranded DNA (anti-dsDNA) Abs and fatal LN (30, 31) . To study the role of iRhom2 in the development of LN, we crossed Rhbdf2 -/-mice with Fcgr2b -/-mice. We found that iRhom2 deficiency protected Fcgr2b -/-mice from severe kidney damage with attenuated TNF and EGFR signaling in the kidneys. Our data demonstrate that activation of the iRhom2/ADAM17 pathway, most likely via cleavage of TNF-α and the EGFR ligand HB-EGF, plays a critical role in mediating tissue inflammation and damage in LN.
Results

iRhom2 deficiency protects Fcgr2b
-/-mice from severe kidney damage. To explore the role of iRhom2 in LN, we studied lupus-prone Fcgr2b -/-mice on a B6 background, which have 80% penetrance of nephritis and 50%-60% mortality by 8 to 9 months of age (30, 31) . 
Rhbdf2
-/-mice. (B-D) Data are shown as mean ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001, 1-way ANOVA with Dunnett's multiple comparisons test. Figure 4 , A and B), followed by gene sets encoding apical junction, apoptosis, IL-6-JAK-STAT3 signaling, and extracellular matrix (ECM) receptor interaction (Supplemental Figure 3, B-D) . Indeed, the highly upregulated genes included profibrotic factors, such as collagen type I α 1 (Col1a1), collagen type III α 1 (Col3a1), actin α 2 smooth muscle (Acta2), connective tissue growth factor (Ctgf), fibronectin 1 (Fn1), and tissue growth factor β 1 (Tgfb1), and inflammatory cytokines/chemokines, such as neutrophil chemoattractant Cxcl1, lymphocyte chemoattractant Cxcl13, growth factor for macrophages and monocyte IL-34 (Il34), and renal injury biomarker lipocalin 2 (Lcn2) ( Figure 4B ). Hierarchical clustering of EMT, TNF signaling, and inflammatory response gene sets indicated distinct expression patterns in the Fcgr2b -/-kidneys compared with the other groups (Supplemental Figure 4) . Absence of iRhom2 significantly Figure 4A and Supplemental Figure 3A) . 
-/-mice compared with WT mice, while Ifna and Ifnb were not significantly induced in the spleens (Supplemental Figure 6 , B and C). Thus, iRhom2 deficiency does not appear to affect STING signaling or the type I IFN pathway in Fcgr2b -/-mice. In addition, we found markedly increased expression of Rhbdf2 in Fcgr2b -/-kidneys compared with other groups by both RNA-seq and quantitative real-time PCR (qPCR) ( Figure 5C ), along with markedly increased expression of ADAM17 proteins ( Figure 5D ). When we examined the public transcriptome database, we discovered that Rhbdf2 mRNA was significantly upregulated in the kidneys from LN patients compared with healthy donors, and it was also higher in nephrotic than subnephrotic patients (Supplemental Figure 7, A 
-/-kidneys (data not shown). We also found substantial downregulation of genes involved in oxidative phosphorylation and fatty acid metabolism in Fcgr2b -/-kidneys, a finding consistent with reports on the crucial role of defective fatty acid metabolism in kidney fibrosis (32) . Importantly, the expression of these genes was restored in iRhom2-deficient Fcgr2b -/-kidneys (Supplemental Figure 5A) .
Recently, iRhom2 was shown to regulate the trafficking and stability of stimulator of IFN genes (STING), and iRhom2-deficient mice showed reduced production of type I IFN and IL-6 in response to DNA virus infection (33) . In the current study, IFN gene signatures were induced to similar levels in Fcgr2b -/-and Fcgr2b
-/-kidneys (Supplemental Figure 5B) , with the highest FC present in the IFN-inducible gene Ifi202b (Supplemen- 
Rhbd2
-/-mice. Data are shown as mean ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001, 1-way ANOVA with Dunnett's multiple comparisons test (A-E), 2-tailed unpaired Student's t test (F). Figure 8A) . Similarly to what was seen in whole kidney, GSEA identified genes involved in TNF signaling highly upregulated in Fcgr2b -/-macrophages. Gene sets associated with cell cycle regulation, including E2F and Myc targets, were also upregulated (Supplemental Figure 8B ).
Comparison of differentially expressed genes in Fcgr2b -/-versus WT mice revealed 381 genes shared between macrophages and kidneys. Using Library of Integrated Network-Based Cellular Signatures (LINCS) (http://www.lincsproject.org/) gene sets, we determined that the shared 381 genes were enriched for genes induced by EGFR ligands, including EGF, TGF-α, betacellulin (BTC), and HB-EGF as well as for TNF-α, IL-1, and PDGF ( Figure 7A ). Among the above-listed EGFR ligands, HB-EGF is the only iRhom2/ ADAM17-selective substrate (8) . As expected, deletion of iRhom2 reduced expression of HB-EGF-induced genes in both macrophages and kidneys ( Figure 7B ). These results support the notion that the EGFR (likely via HB-EGF) and TNF signaling pathways are strongly activated in Fcgr2b -/-kidney tissues and macrophages and that loss of iRhom2 offers protection from the dysregulation of these key pathogenic pathways.
Activation of EGFR signaling contributes to progressive renal injury in Fcgr2b
-/-mice. Overexpression of EMT and ECM receptor pathways in Fcgr2b -/-kidneys can lead to accumulation of ECM, activation of myofibroblasts, and end-stage fibrosis, processes described in chronic kidney diseases. These processes require EGFR signaling, and cleavage of most EGFR ligands is mediated by ADAM17 (22, 36, 37) . To determine whether iRhom2/ADAM17-dependent EGFR activation occurs in Fcgr2b -/-kidneys, we assessed phosphorylation of EGFR and ERK1/2, the main kinase downstream of EGFR signaling. Kidneys from aged Fcgr2b -/-mice demonstrated increased EGFR and ERK1/2 phosphorylation compared with WT and Rhbdf2 -/-kidneys, which were abrogated in Fcgr2b
Rhbdf2
-/-kidneys ( Figure 8A ). Among EGFR ligands shed by iRhom2/ADAM17, only Hbegf was significantly increased in the kidneys of Fcgr2b -/-mice commice revealed increased numbers of macrophages ( Figure 3C ). Immunohistochemical staining with F4/80 showed that macrophages accumulated around glomeruli and tubulo-interstitium in aged (7 to 9 months old) Fcgr2b -/-kidneys ( Figure 6A ). These macrophages also have increased expression of the cell activation marker CD11b ( Figure 6B ). Both the number of kidney macrophages and CD11b levels were significantly lower in Fcgr2b
-/-mice ( Figure 6 , A and B). Moreover, CD11b levels in kidney macrophages positively correlated with proteinuria levels ( Figure 6C ), suggesting an association between activated kidney macrophages and tissue injury.
To further explore the role of iRhom2 in the function of kidney macrophages in Fcgr2b -/-mice, we analyzed transcriptomes of kidney macrophages (Supplemental Figure 8 and sorting strategy in Supplemental Figure 1C ). Similarly to our findings in the whole kidneys, 2,144 genes were differentially expressed in Fcgr2b -/-kidney macrophages compared with WT controls (P < 0.01, FC = 2), while only 212 genes were differentially expressed between Fcgr2b -/- 
-/-mice, as assessed by RNA-seq and confirmed by qPCR ( Figure 8B ). Neither epiregulin (Ereg) nor amphiregulin (Areg), 2 other iRhom2/ADAM17-dependent EGFR ligands, were detected. Tgfα, an iRhom1 and iRhom2/ADAM17 substrate (25) , and Btc, an ADAM10 substrate, as well as their common receptor Egfr, were highly expressed at equal levels in the kidneys of all 4 strains. The ADAM10 substrate Egf was downregulated in the Fcgr2b -/-kidneys ( Figure 8B ). To determine whether EGFR activation is required for renal damage in Fcgr2b -/-mice, we treated Fcgr2b -/-mice with erlotinib, an EGFR tyrosine kinase inhibitor (10 mg/kg i.p. 3 times/wk for 12 weeks) beginning at 6 months of age, after the onset of proteinuria. Erlotinib treatment protected mice from serious kidney damage ( Figure 9 , A-C), but did not alter serum anti-dsDNA Ab levels ( Figure 9D ). Renal function assessed by BUN was preserved ( Figure 9A ), but levels of proteinuria were not affected ( Figure 9B ). Histological analysis of kidneys showed marked improvement in tubulo-interstitial injury and a trend toward glomerular recovery ( Figure 9C ), suggesting that EGFR signaling participates in irreversible late-stage kidney damage. Moreover, erlotinib treatment reduced expression of Ctgf and Col1a1, key factors involved in EMT (38, 39) , in kidneys of Fcgr2b -/-mice to levels similar to those in Fcgr2b -/-Rhbdf2 -/-mice ( Figure 9E ). That erlotinib effectively blocked EGFR signaling was confirmed by decreased phosphorylation of EGFR and ERK1/2 in kidney lysates ( Figure 9F ). Taken together, these findings suggest that activation of EGFR plays an essential role in kidney injury in Fcgr2b -/-mice. To determine whether HB-EGF expression is also upregulated in kidneys from patients with LN, we studied kidney biopsies with class IV and V nephritis. Consistent with previous reports (13), we found increased expression of HB-EGF in the glomerular crescents of LN patients. In addition, the interstitial infiltrates of LN kidneys were strongly stained for HB-EGF, as compared with our positive control patients with pauci-immune crescentic glomerulonephritis (anti-neutrophil cytoplasmic Ab-associated [ANCA-associated] vasculitis), who had HB-EGF overexpression only in the crescents ( Figure 10A and Supplemental Table 1 ). Importantly, and consistent with the RNA-seq data from kidney macrophages in Fcgr2b -/-mice, HB-EGF colocalized with CD68 + macrophages in the interstitium of LN patients ( Figure 10B and Supplemental Figure 7C ) . Moreover, the intensity of HB-EGF 
-/-mice. Data are shown as mean ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001, 1-way ANOVA with Dunnett's multiple comparisons test except RNA-seq data.
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Activation of TNF-α is required for kidney damage in Fcgr2b
-/-mice. We next assessed the contribution of TNF-α, a major substrate of iRhom2/ADAM17, to kidney damage in Fcgr2b -/-mice. At the level of transcription, Tnf and its receptors TNF receptor I (TNFRI, gene name Tnfrsf1a) and II (TNFRII, gene name Tnfrsf1b) were markedly increased in aged Fcgr2b -/-kidneys. Deficiency of iRhom2 did not alter expression of Tnf and Tnfrsf1b, but reduced Tnfrsf1a levels ( Figure 11A ). Given that the proinflammatory signaling of TNF-α is predominantly mediated via soluble TNF/TNFRI binding (40) and that the highly upregulated TNF signaling pathway in Fcgr2b To determine whether TNF-α is required for development of LN in Fcgr2b -/-mice, we treated these animals with a TNF-α blocker, murine p75TNFR:Fc (41, 42) , starting at 6 months of age, once proteinuria started to develop. After 12 weeks of treatment, mice receiving p75TNFR:Fc showed significantly reduced BUN levels, although the change in proteinuria levels was not significant (Figure 11B) . Treatment with p75TNFR:Fc also markedly diminished tubulo-interstitial damage and led to a trend toward improved glomerular scores ( Figure 11C ). There was a modest, but not significant, increase in serum anti-dsDNA Ab levels in mice treated with p75TNFR:Fc ( Figure 12A ). Kidney expression of profibrotic factors Ctgf and Col1a1, measured by qPCR ( Figure 12B ), and fibronectin, measured by Western blot (Figure 12C ), was reduced by p75TN-FR:Fc treatment. Renal expression of Hbegf was also decreased with the treatment (Figure 12B ). Moreover, activation of EGFR signaling in the kidneys, as indicated by phosphorylation of EGFR, was diminished in p75TNFR:Fc-treated mice, but phosphorylation 
Rhbdf2
-/-mice. Data are shown as mean ± SEM. *P < 0.05; ****P < 0.0001, 1-way ANOVA with Dunnett's multiple comparisons test. (C) Correlation analysis of kidney macrophage CD11b levels and proteinuria. n = 11 WT, n = 6 Rhbdf2
-/-mice, 41 mice in total. Spearman's correlation, 2-tailed. Deficiency of iRhom2 in Fcgr2b -/-mice prevented major renal pathology, including proteinuria, excess deposition of ECM, infiltration of inflammatory cells, and structural damage of the glomeruli, but did not affect splenic immune cell expansion, production of anti-dsDNA Abs, or kidney deposition of IC and C3, suggesting that protection is achieved by blocking the effector arm of the disease.
TNF signaling was markedly upregulated in the kidneys of Fcgr2b -/-mice, and TNF-α blockade prevented severe kidney damage, demonstrating that activation of TNF signaling is an important mediator of injury in Fcgr2b -/-mice. Importantly, activation of the TNF signaling pathway in Fcgr2b -/-kidneys was diminished in the absence of iRhom2. As an early and potent master cytokine in tissue inflammation, TNF-α not only triggers production of numerous cytokines, including CXCL1, CXCL13, and IL-34, which further recruit inflammatory cells and amplify injury (2, 45) , but can also cause direct injury in podocytes (46) . TNF-α blockade using murine p75TNFR:Fc prevented interstitial, but not glomerular, injury in Fcgr2b -/-mice. In previous studies, this intervention has been shown to prevent both glomerular and interstitial damage in NZB/W mice (47) . Lack of protection for proteinuria in the p75TNFR:Fc-treated Fcgr2b -/-mice could be due to strain differences in pathogenesis, disease severity, or TNF-α levels in different murine models of SLE (48) . In addition, given that deficiency of iRhom2 markedly reduced proteinuria levels in Fcgr2b -/-mice, whereas blockade of TNF-α did not, glomerular injury associated with development of proteinuria may involve iRhom2-dependent, TNF-α-independent mechanism(s) in these mice. Whether blocking iRhom2 is beneficial to LN needs to be corroborated in other murine models of SLE in future studies.
In patients with lupus, treatment with TNF-α blockers had variable results and remains controversial. Although proteinuria was reported to be ameliorated in most patients with LN treated of ERK1/2 was not significantly reduced ( Figure 12C ). These data suggest that iRhom2/ADAM17-dependent shedding of TNF-α and subsequent activation of TNF-α signaling contribute to the pathogenesis of renal damage in Fcgr2b -/-mice. Given that both EGFR and TNF-α signaling appear to be critical mediators of kidney injury that leads to renal failure in Fcgr2b -/-mice and that EGFR phosphorylation is reduced with TNF blockade, we tested to determine whether TNF-α can directly activate EGFR in kidney cells. We found that treatment of the kidney podocyte cell line MPC5 (43) with TNF-α led to phosphorylation of both EGFR and ERK, which was abrogated by pretreatment cells with marimastat, a metalloproteinase inhibitor. More importantly, siRNA knockdown of iRhom2 abolished TNF-α-induced EGFR and ERK phosphorylation ( Figure 13 ). Similar results were obtained in kidney tubular epithelial cell line C1 (44) (Supplemental Figure 9) . Indeed, iRhom2-deficient mice had significantly lower expression of mature ADAM17 in their nephrons (glomeruli and tubules) (Supplemental Figure 10) , further supporting the possibility that lack of iRhom2/ADAM17-dependent shedding in resident kidney cells, such as podocytes and tubular cells, also contributes to the protection of TNF-α-mediated transactivation of EGFR in Fcgr2b
-/-mice.
Discussion
Applying genetic and pharmacologic approaches to the Fcgr2b -/-mouse model of LN (30, 31), we established a pivotal role for iRhom2, a key regulator of ADAM17, in the pathogenesis of LN. We found that Fcgr2b -/-mice lacking iRhom2 are protected from progressive renal injury, likely by simultaneous blockade of TNF-α and EGFR signaling. We thus provide what we believe is the first proof of concept that targeting iRhom2 can protect from the deleterious consequences of dysregulation of these 2 major signaling pathways, thereby revealing a promising new target for attenuating LN. 
Rhbdf2
-/-mice). Data are shown as mean ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001, 1-way ANOVA with Dunnett's multiple comparisons test. ND, not detected. -/-mice, driving pathways that cause aberrant tissue repair and fibrosis (13, 16, 37, 51, 52) . That proteinuria was not affected by erlotinib in this study suggests that EGFR signaling is not mandatory for pathological urinary protein loss, as previously described for LPS-induced proteinuria (13), although EGFR does contribute to pathogenesis of some proliferative glomerular disorders (37) .
Various EGFR ligands have been implicated in EGFR activation in other experimental models of nephritis (37) . However, only Hbegf was highly upregulated in diseased kidneys from Fcgr2b -/-mice. HB-EGF is constitutively expressed along the nephrons and is induced in TLR-or IC-stimulated macrophages (53) (54) (55) (56) . Ours is the first work, to our knowledge, to implicate kidney macrophages as a critical source for HB-EGF in progressive kidney injury of LN.
with TNF-α inhibitors, in some patients, disease was exacerbated with the emergence of auto-Abs. This is likely because anti-TNF-α Abs (e.g., infliximab and adalimumab) and soluble TNFRFc (etanercept) bind to both soluble TNF-α, which transduces a proinflammatory signal, and membrane-bound TNF-α, which mediates regulatory signals (40, (48) (49) (50) . Blockade of iRhom2 has the advantage of specifically inhibiting generation of soluble TNF-α and thereby primarily targeting the proinflammatory pathway while circumventing adverse effects of complete TNF-α inhibition (40) . That anti-dsDNA Ab levels were not altered in iRhom2-deficient Fcgr2b -/-mice while p75TNFR:Fc treatment led to a moderate increase in these Abs further supports the concept that effector functions of soluble TNF-α are blocked.
Activation of EGFR signaling in Fcgr2b -/-kidneys would explain the upregulation of tissue-remodeling genes, including EMT, apical junction, and ECM receptor interaction, which are signs of end-stage changes in chronic kidney diseases (37) . Selec- Moreover, TNF-α transactivates EGFR/ERK1/2 in podocyte and tubular cell lines, as observed previously (58, 59) , suggesting that TNF-α can further amplify EGFR signaling and its detrimental effects on LN. Importantly, this transactivation is iRhom2/ADAM17 dependent. Moreover, transactivation of the EGFR by other factors, such as CXCL1 and TNF-like weak inducer of apoptosis (TWEAK) (60, 61) , and most likely also via iRhom2/ADAM17, could also contribute to EGFR activation in Fcgr2b -/-kidneys. In addition, other iRhom2/ADAM17 substrates, such as IL-6R, may also contribute to renal damage in this model (62) (63) (64) , which requires future study.
The common regulator of TNF-α and EGFR ligands, ADAM17, has been considered as a potential therapeutic target for chronic kidney diseases, particularly progressive fibrosis (15) (16) (17) . In diseased Fcgr2b -/-kidneys, both ADAM17 and iRhom2 were upregulated, and iRhom2 was overexpressed in the kidneys of LN patients. Previous studies by our group indicate that iRhom2-deficient macrophages lack ADAM17 activity (26, 28) . Our data here also show a marked loss of ADAM17 expression in the nephrons of mice lacking iRhom2. Thus, glomerular and tubular cells as well as leukocytes, such as macrophages, may both contribute to iRhom2/ADAM17-dependent shedding of its substrates, including HB-EGF. Compared with a kidney fibrosis model in which blockade of ADAM17 protected against fibrosis, but not elevated proteinuria or BUN or KIM-1/TIM-1 expression (17), iRhom2 deficiency rescued both renal function and profibrotic parameters. Importantly, iRhom2 deficiency seems to be more potent than erlotinib or p75TNFR:Fc alone. Hence, targeting iRhom2 could provide significant advantages over individually targeting ADAM17, TNF, or EGFR, all of which have been reported to cause adverse effects (37, 65, 66) .
Recently, iRhom2 has also been reported to function as a regulator of STING (33) , yet mechanistically, our data did not support engagement of iRhom2/STING in kidney damage of Fcgr2b -/-mice. Inactivation of the cGAS/STING pathway in murine lupus models is often associated with changes in anti-dsDNA Ab production and lymphoid hypertrophy (67) (68) (69) , while iRhom2 deficiency did not affect anti-dsDNA Ab production in Fcgr2b -/-mice. Moreover, we found no change in the type I IFN signature in iRhom2-deficient Fcgr2b -/-mice. In summary, we provide what we believe is the first proofof-concept that iRhom2 is critical for the development of LN in Fcgr2b -/-mice, most likely by activating ADAM17-dependent Consistent with studies in Fcgr2b -/-mice, which recapitulate the human condition with glomerular and interstitial inflammation and fibrosis (30, 31) , our studies of human LN biopsies revealed that expression of HB-EGF occurred in both the glomerular crescents and interstitial cells. Interstitial HB-EGF colocalized mainly with macrophages. Most importantly, interstitial HB-EGF expression in human LN biopsies was associated with chronicity index, a measure of signs of irreversible kidney damage and poor prognosis. In nephrotoxic serum-induced nephritis, it is thought that HB-EGF produced from podocytes and parietal epithelial cells triggers activation of EGFR in podocytes and leads to rapidly progressive glomerulonephritis, whereas endothelium-derived HB-EGF drives angiotension II-induced renal fibrosis (13, 57) . Collectively, our results indicate that both renal macrophages and resident kidney cells contribute to production of HB-EGF and subsequent EGFR signaling in Fcgr2b -/-kidneys. Importantly, ADAM17-dependent stimulated release of HB-EGF is controlled by iRhom2 (25), providing a compelling explanation for why inactivation of iRhom2 affects dysregulated EGFR signaling in this model.
Gene-expression analysis of kidney macrophages from Fcgr2b -/-mice further supports results from whole kidneys regarding TNF-α and HB-EGF/EGFR signaling. Since macrophages are a major source of TNF-α in response to IC or TLR stimulation, diminished TNF signaling in Fcgr2b
-/-kidney macrophages provides another mechanism by which the iRhom2/ ADAM17 pathway is a crucial contributor to pathogenesis of LN. (A) HB-EGF staining in the interstitium and glomerular crescents of LN and ANCA patients (n = 9 LN class IV patients with crescents, n = 10 ANCA patients). Data are shown as mean ± SEM. ***P < 0.001, 2-tailed unpaired Student's t test. Scale bars: 50 μm (upper panels); 100 μm (lower panels). (B) Sequential HB-EGF and CD68 staining in the kidney interstitium of LN patients. Arrows indicate overlapping staining of HB-EGF (red nuclei) and CD68 (white cytoplasm). Scale bars: 100 μm (top); 50 μm (bottom). (C) Correlation of interstitial HB-EGF and chronicity of lupus patients. n = 24 LN patients (n = 18 class IV and n = 6 class V). Two-tailed Spearman's correlation.
Volume 128 Number 4 April 2018 histology and pathology, kidneys were fixed in 10% neutral buffered formalin (Sigma-Aldrich) and paraffin-embedded kidney sections (4 μm) were stained with PAS or Masson's Trichrome (Sigma-Aldrich). Glomerular and tubular injury were assessed in a blinded manner by an experienced nephron-pathologist (M. Madaio) with a scoring system ranging from 0 to 4 (71) . For EM analysis, kidney sections were examined under a JEOL JEM 1400 electron microscope equipped with a digital imaging system. Immunofluorescence and IHC of mouse kidneys. To detect kidney deposition of IC and C3, frozen kidney sections were stained with FITC-conjugated anti-mouse C3 (Cedarlane, catalog CL7503F) or Alexa Fluor 594-conjugated goat anti-mouse IgG (Abcam, catalog ab150116). For podocin staining, frozen kidney sections were stained with rabbit anti-mouse podocin Abs (Sigma-Aldrich, catalog P0372). Alexa Fluor 594-conjugated goat anti-rabbit IgG (Abcam, catalog ab150080) was used as s secondary Ab. Photographs were taken from a Nikon Eclipse E600 fluorescence microscope. Kidney KIM-1/TIM-1 and F4/80 were stained by immunohistochemistry. Briefly, paraffin-embedded kidney sections were deparaffinized. After Ag retrieval, slides were blocked and incubated with rabbit anti-mouse KIM-1/ TIM-1 (Novus, catalog NBP1-76701) or rat anti-mouse F4/80 (Abcam, catalog ab16911). Biotin-conjugated secondary Abs were then applied. The standard ABC method (R&D Systems) was used for detection. Photographs were taken on a Nikon Eclipse E400 light microscope. ImageJ software (NIH) was used to quantify intensity of staining.
Flow cytometry analysis. Single-cell suspensions were prepared from spleen and kidney. Briefly, for splenocytes, single-cell suspension was obtained by forcing the spleen through a 70 μm cell strainer. Red blood cells were then lysed with ammonium-chloride-potassium (ACK) TNF-α and HB-EGF/EGFR pathways, and we present evidence for increased HB-EGF expression in severe human LN. These results provide the rationale for future studies of iRhom2 in human lupus patients. Blockade of iRhom2 offers a mechanism for inhibiting 2 important mediators of renal damage as well as a new therapeutic approach to LN.
Methods
Animal experiments. Fcgr2b
-/-mice on a C57BL/6 background previously described (30, 31) were purchased from the Jackson Laboratory. C57BL/6 Rhbdf2 -/-mice bred in-house (26) 
Rhbdf2
-/-mice) were used in the study of lupus development from 3 to 9 months of age. For p75TNFR:Fc and erlotinib treatment, female Fcgr2b -/-mice were treated with murine p75TNFR:Fc (a gift from Amgen, 50 μg i.p. injection 3 times/wk, PBS as control) or erlotinib (LC Laboratories, catalog E4997) dissolved in 5% N-methyl-2-pyrrolidone, 45% polyethylene glycol 400, and 50% dextrose in water (10 mg/kg, i.p. injection, 3 times/wk, vehicle as control) starting at 6 months of age for 12 weeks. Mice were housed in the animal facility of Weill Cornell Medicine in accordance with NIH guidelines.
To assess development of lupus-like syndromes, mouse serum was collected and tested for anti-dsDNA IgGs by ELISA, as previously described (70) , proteinuria was assessed by measuring the urine albumin/creatinine ratio using the Albuwell M Test Kit and Creatinine Companion Kit (Exocell), and BUN was measured in mouse serum on an AU 680 Beckman Coulter Analyzer. Mice were extensively perfused with 50 ml of PBS before harvesting kidneys for histology, immunohistology, flow cytometry, and isolation of RNA. For kidney RNA-seq and data analysis. For RNA-seq in mouse kidneys, total RNA was extracted with an RNeasy Mini Kit (QIAGEN). Library preparation and sequencing were performed by Genomics Resources Core Facility at Weill Cornell Medicine using the TruSeq RNA Library Prep Kit (Illumina) followed by single-read sequencing on the Illumina HiSeq 2500 instrument.
To sort kidney macrophages for RNA-seq, kidneys from 7-to 9-month-old mice were first minced and digested with collagenase B (Roche) for 45 minutes at 37°C. Macrophages were enriched by centrifuging cells in 40% percoll/PBS (v/v). Cells were centrifuged at 1000 g for 15 minutes at room temperature with low acceleration and no brake. Cells were stained with fluorochrome-conjugated anti-mouse Abs, and CD45 . Cells were cultured as previously described (43, 44) . Cells were pretreated with 5 μM of the metalloprotease inhibitor marimastat (Sigma-Aldrich) for 15 minutes or transfected with siRNA (Life Technologies) 24 hours prior to stimulation with 20 ng/ml of mouse recombinant TNF-α (Peprotec) for 10 minutes.
Isolation of nephrons. Mice were injected with 100 μl of clodronate liposome i.v. to deplete tissue macrophages 7 days before euthanasia. Mice were thoroughly perfused with PBS. Minced kidneys were digested with 1 mg/ml of collagenase A (Sigma-Aldrich) in PBS for 30 minutes at 37°C. The solution was then successively passed through fine mesh metal sieves (Endecotts) with a diameter of 250 μm, 106 μm, and 53 μm. The nephrons containing glomeruli and tubules were collected by rinsing from the 53 μm sieve. Collected nephrons were lysed with lysis buffer containing protease inhibitors. The purity of the nephrons was confirmed under a Nikon TMS inverted phase contrast microscope.
Human kidney biopsies. Human kidney biopsies were randomly selected from the biobank of the Department of Pathology at the Academic Medical Center, University of Amsterdam. Biopsies were selected based on tissue diagnosis (18 cases of LN class IV, 6 cases of LN class V, 10 cases of ANCA-associated pauci immune crescentic glomerulonephritis, and 4 controls with normal kidney tissues from patients who underwent nephrectomy because of renal cell carcinoma). All biopsies contained a minimum of 10 glomeruli.
Histological parameters were scored in a blinded fashion by an experienced nephropathologist (J.J.T.H. Roelofs). LN was classified according to the WHO/RPS 2003 classification (74) . Chronicity indices were determined according to the method of Austin et al. (75) . Workbench 7.5 (QIAGEN). DE analysis was performed using EdgeR (72) with the unique exon read counts as a measure of gene-expression levels. Genes with less than 3 counts per million (cpm) in all replicates were filtered out prior to DE analysis. The feature counts were normalized to the library size using the weighted trimmed mean of M values methods (73) . Analysis of multidimensional scaling plot indicated good separation and clustering of relevant genotypes with no visible batch effect. A quasi-likelihood negative binomial generalized log-linear model was fit to read counts for each gene. An empirical Bayes quasi-likelihood F test or a likelihood ratio test was performed gene-wise to evaluate the significance of differences in expression between analyzed groups. Genes with a Benjamini-Hochberg false discovery rate-corrected (FDR-corrected) P value of less than 0.01 and at least 2-fold expression change were considered to be differentially expressed.
GSEA was performed using the difference of log-transformed cpm as a ranking metric using Molecular Signatures DataBase v 5.2 (Broad Institute). Gene sets with 15 to 1,000 genes were included in analysis. Nominal P values were FDR corrected, and gene sets with an FDR of less than 0.01 were used to create a GSEA enrichment plot using customized R script.
All original RNA-seq data were deposited in the NCBI's Gene Expression Omnibus database (GEO GSE107705).
Quantitative real-time RT-PCR (qPCR). Total RNA was extracted with an RNeasy Mini Kit (QIAGEN) from mouse kidneys. cDNA was further synthesized with the Superscript III First-Strand Synthesis System for reverse transcription PCR (QIAGEN). qPCR was performed in duplicate with the SYBR green method on the ABI PRISM 7900HT Sequence Detection System (Applied Biosystems). The expression of each gene was normalized to the control gene, Gapdh. A last step dissociation curve was performed to Figure 13 . TNF-α transactivates EGFR via iRhom2/ADAM17 in podocyte cell line. MPC5 cells pretreated with marimastat (MM) or transfected with siRNA were stimulated with mouse TNF-α. Expression of p-EGFR, EGFR, p-ERK1/2, and ERK1/2 was assessed by Western blot. Densitometry of p-EGFR and p-ERK1/2 expression was calculated as ratios against total EGFR or ERK1/2, respectively. Data are shown as mean ± SEM. n = 3 independent experiments. *P < 0.05; **P < 0.01, 1-way ANOVA with Dunnett's multiple comparisons test.
IHC of HB-EGF in human kidney samples. Paraffin-embedded tissue sections (4 μm) were deparaffinized. Antigen retrieval was performed by boiling sections in a buffer containing 10 mM TRIS and 1 mM EDTA (pH 9.0) for 10 minutes. Sections were labeled with rabbit anti-human HB-EGF (Sigma-Aldrich), followed by labeling with an HRP-labeled goat anti-rabbit IgG (Immunologic), and stained with DAB (Sigma-Aldrich). Nuclei were counterstained with hematoxylin, and slides were mounted with VectorMount (Vector Laboratories). All control specimens with normal kidney tissues were negative for HB-EGF staining (data not shown).
Sequential IHC of human kidney samples. Sequential IHC was performed as previously described (76) . Briefly, paraffin-embedded human kidney sections (4 μm) were deparaffinized. Antigen retrieval was performed by boiling sections in a buffer containing 10 mM TRIS and 1 mM EDTA (pH 9.0) for 10 minutes. Sections were labeled and stained with Vector NovaRED (Vector Laboratories), nuclei were counterstained with hematoxylin, and slides were mounted with VectorMount (Vector Laboratories), after which slides were scanned on a digital slide scanner (IntelliSite Pathology Ultra Fast Scanner, Philips). The coverslip was removed, and Ab and staining were stripped by incubation for 30 minutes in 1 M Tris-HCl (pH 7.5) supplemented with 2% (v/v) sodium dodecyl sulfate and 0.7% (v/v) β-mercaptoethanol at 50°C, followed by rinsing in tap water. Complete removal of the stain was ensured by visual inspection. Sequential staining was performed on the same section. Primary Abs, sequentially applied, were rabbit anti-human HB-EGF (Sigma-Aldrich, catalog SAB1302715), mouse anti-human CD79a (DAKO, catalog GA62161-2), rabbit anti-human CD3 (Thermo Fisher Scientific, catalog PA5-28313), and mouse anti-human CD68 (DAKO, catalog M081401-2). Primary Abs were labeled using HRP-labeled antimouse or anti-rabbit IgG (Immunologic).
Composite images were generated from sequential IHC. Digital images of individual IHC staining performed on a single section were stacked and registered in the Fiji software package (http://fiji.sc/ Fiji) using the StackReg plugin. The inversed red color channel generated using the Colour Deconvolution plugin 20 was used to create a false color composite image of the stacked images. The intensity of HB-EGF staining of interstitial cells was scored in a semiquantitative fashion from 0 to 3 in at least 7 high-power fields per biopsy section.
Statistics. Data were expressed as mean ± SEM. The D'Agostino-Pearson omnibus normality test was used to test normal distribution. To com-
